Cordonnier D, Alix J L, Schaerer R, Swiercz P, Vialtel P, Bayle F
Presse Med. 1984 Apr 28;13(18):1141-5.
The renal toxicity of antitumoral drugs is an increasingly disturbing problem. These drugs are now prescribed in an ever wider variety of cases, and delayed renal reactions, previously unknown, are revealed by the longer survivals obtained. For a number of years, patients whose cancer had been cured have been placed under haemodialysis on account of drug-induced renal failure. The renal toxicity of cisplatinum, nitrosoureas and methotrexate is well-known, but mitomycin C is also capable of inducing permanent renal failure; the delayed toxicity of this drug explains that it has long been underestimated. This example emphasizes the need for close co-operation between oncologists, nephrologists and pharmacologists in order to determine, for each patient, the most effective treatment with the minimum of side effects.
抗肿瘤药物的肾毒性是一个日益令人不安的问题。现在这些药物在越来越多的病例中被使用,并且由于患者存活时间延长,以前未知的延迟性肾反应也显现出来。多年来,一些癌症已治愈的患者因药物性肾衰竭而接受血液透析。顺铂、亚硝基脲和甲氨蝶呤的肾毒性是众所周知的,但丝裂霉素C也能够诱发永久性肾衰竭;这种药物的延迟毒性解释了它长期以来一直被低估的原因。这个例子强调了肿瘤学家、肾病学家和药理学家密切合作的必要性,以便为每个患者确定副作用最小的最有效治疗方法。